Literature DB >> 9988761

Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35).

A E Oran1, D E Isenman.   

Abstract

Mapping approaches employing blocking antibodies and synthetic peptides have implicated the 727-767 segment at the NH2 terminus of C3b alpha'-chain as contributing to the interactions with factor B, factor H, and CR1. Our previous mutagenesis study on the NH2-terminal acidic cluster of this segment identified residues Glu-736 and Glu-737 as contributing to the binding of C3b to factor B and CR1 but not factor H. We have now extended the charged residue mutagenic scan to cover the remainder of the segment (738-767) and have assessed the ability of the C3b-like C3(H2O) form of the mutant molecules to interact with factor H, CR1, and membrane cofactor protein (MCP) using a cofactor-dependent factor I cleavage assay as a surrogate binding assay. We have found that the negatively charged side chains of Glu-744 and Glu-747 are important for the interaction between C3(H2O) and factor H, a result in general agreement with an earlier synthetic peptide study (Fishelson, Z. (1991) Mol. Immunol. 28, 545-552) which implicated residues within the 744-754 segment in H binding. The interactions of the mutants with soluble CR1 (sCR1) revealed two classes of residues. The first are residues required for sCR1 to be an I cofactor for the first two cleavages of alpha-chain. These are all acidic residues and include the Glu-736/Glu-737 pair, Glu-747, and the Glu-754/Asp-755 pairing. The second class affects only the ability of sCR1 to be a cofactor for the third factor I cleavage and include Glu-744 and the Lys-757/Glu-758 pairing. The dominance of acidic residues in the loss-of-function mutants is striking and suggests that H and CR1 contribute basic residues to the interface. Additionally, although there is partial overlap, the contacts required for CR1 binding appear to extend over a wider portion of the 727-767 segment than is the case for factor H. Finally, none of the mutations had any effect on the interaction between soluble MCP and C3(H2O), indicating that despite its functional homology to H and CR1, MCP differs in its mode of binding to C3b/C3(H2O).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988761     DOI: 10.1074/jbc.274.8.5120

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Structural transitions of complement component C3 and its activation products.

Authors:  Noritaka Nishida; Thomas Walz; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

2.  Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.

Authors:  Kenneth J Katschke; Scott Stawicki; Jianping Yin; Micah Steffek; Hongkang Xi; Lizette Sturgeon; Philip E Hass; Kelly M Loyet; Laura Deforge; Yan Wu; Menno van Lookeren Campagne; Christian Wiesmann
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

3.  A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.

Authors:  Sophie Chauvet; Lubka T Roumenina; Sarah Bruneau; Maria Chiara Marinozzi; Tania Rybkine; Elizabeth C Schramm; Anuja Java; John P Atkinson; Jean Claude Aldigier; Frank Bridoux; Guy Touchard; Veronique Fremeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2015-10-15       Impact factor: 10.121

4.  Disruption of the alternative pathway convertase occurs at the staphylococcal surface via the acquisition of factor H by Staphylococcus aureus.

Authors:  Julia A Sharp; Kenji M Cunnion
Journal:  Mol Immunol       Date:  2010-12-15       Impact factor: 4.407

5.  Identification of functional domains in kaposica, the complement control protein homolog of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8).

Authors:  Jayati Mullick; Akhilesh K Singh; Yogesh Panse; Vivekanand Yadav; John Bernet; Arvind Sahu
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Authors:  Elizabeth C Schramm; Lubka T Roumenina; Tania Rybkine; Sophie Chauvet; Paula Vieira-Martins; Christophe Hue; Tara Maga; Elisabetta Valoti; Valerie Wilson; Sakari Jokiranta; Richard J H Smith; Marina Noris; Tim Goodship; John P Atkinson; Veronique Fremeaux-Bacchi
Journal:  Blood       Date:  2015-01-21       Impact factor: 22.113

7.  Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b.

Authors:  John Bernet; Jayati Mullick; Yogesh Panse; Pradeep B Parab; Arvind Sahu
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.

Authors:  Vasil V Vasilev; Remi Noe; Marie-Agnes Dragon-Durey; Sophie Chauvet; Valentin J Lazarov; Boriana P Deliyska; Veronique Fremeaux-Bacchi; Jordan D Dimitrov; Lubka T Roumenina
Journal:  J Biol Chem       Date:  2015-08-05       Impact factor: 5.157

9.  Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.

Authors:  Jin Wu; You-Qiang Wu; Daniel Ricklin; Bert J C Janssen; John D Lambris; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

10.  CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis.

Authors:  Masanori A Murayama; Shigeru Kakuta; Asuka Inoue; Naoto Umeda; Tomo Yonezawa; Takumi Maruhashi; Koichiro Tateishi; Harumichi Ishigame; Rikio Yabe; Satoshi Ikeda; Akimasa Seno; Hsi-Hua Chi; Yuriko Hashiguchi; Riho Kurata; Takuya Tada; Sachiko Kubo; Nozomi Sato; Yang Liu; Masahira Hattori; Shinobu Saijo; Misao Matsushita; Teizo Fujita; Takayuki Sumida; Yoichiro Iwakura
Journal:  Nat Commun       Date:  2015-09-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.